Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Video Expert Opinion
Colleague Insights
Living Resources
Conferences
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Access expired on Monday, January 18, 2021

This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.

Already Have An Account? Log in Now

Register Now
Published in Bladder Cancer

Journal Scan / Review · December 16, 2020

Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder

European Urology Oncology

 

 Save  Recommend
 Share

Additional Info

European Urology Oncology
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Eur Urol Oncol 2020 Nov 08;[EPub Ahead of Print], M Rouanne, DF Bajorin, R Hannan, MD Galsky, SB Williams, A Necchi, P Sharma, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated